Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis and treatment of pathologic gambling

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Pathologic gambling (PG) is an impulse control disorder characterized by recurrent and maladaptive gambling behaviors that significantly disrupt the patient’s functioning in the personal, familial, or vocational spheres. Pathologic gambling is estimated to currently affect 1% to 3.4% of the adult US population and is frequently comorbid with substance abuse or dependence, attention-deficit/hyperactivity disorder (ADHD), and affective disorders. Studies show evidence for the involvement of the serotonergic, noradrenergic, and dopaminergic systems in the etiology of PG. Medication treatment studies performed in PG patients demonstrated the short-term efficacy of various serotonin reuptake inhibitors, opioid antagonists, and mood stabilizers in a subsample of adult pathologic gamblers who seek treatment. This review focuses on recent research examining the neurobiology and treatment of PG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Association; 1994.

    Google Scholar 

  2. Blakeslee S: Suicide rate higher in three gambling cities, study says. New York Times. December 16, 1997.

  3. Ciarrocchi J, Richardson R: Profile of compulsive gamblers in treatment: update and comparisons. J Gambling Behav 1989, 5:53–65.

    Article  Google Scholar 

  4. Lesieur HR, Blume SB: Characteristics of pathological gamblers among patients on a psychiatric admissions service. Hosp Community Psychiatry 1990, 41:1–12.

    Google Scholar 

  5. Livingston J: Compulsive Gamblers: Observations on Action and Abstinence. New York: Harper Torchbooks; 1974.

  6. National Council on Problem Gambling: National Council on Problem Gambling Research and Public Policy Committees: Problem and Pathological Gambling in America: The National Picture. Coulmbia, MD: National Council on Problem Gambling; 1997.

    Google Scholar 

  7. Volberg RA: The prevalence and demographics of pathological gamblers: implications for public health. Am J Pub Health 1994, 84:237–241.

    PubMed  CAS  Google Scholar 

  8. Commision on the Review of the National Policy Toward Gambling: In Gambling in America. Washington, DC: US Government Printing Office; 1976.

  9. Lesieur HR, Cross J, Frank M, et al.: Gambling and pathological gambling among college students. Addict Behav 1991, 16:517–527.

    Article  PubMed  CAS  Google Scholar 

  10. Lesieur HR, Klein R: Gambling and pathological gambling among high school students. Addict Behav 1987, 12:129–135.

    Article  PubMed  CAS  Google Scholar 

  11. Shaffer HJ: Estimating the prevalence of adolescent gambling: a quantitative synthesis and guide toward standard gambling nomenclature. J Gambling Stud 1996, 12:193–214.

    Article  Google Scholar 

  12. Lesieur HR: The female pathological gambler. In Gambling Studies and Proceedings of the Seventh International Conference on Gambling and Risk Taking. Edited by Eadington WR. Reno: University of Nevada; 1988.

    Google Scholar 

  13. Lester D: Access to gambling opportunities and compulsive gambling. Int J Addict 1994, 29:1611–1616.

    PubMed  CAS  Google Scholar 

  14. McCormick RA, Russo AM, Ramirez LF, et al.: Affective disorders among pathological gamblers seeking treatment. Am J Psychiatry 1984, 141:215–218.

    PubMed  CAS  Google Scholar 

  15. Linden RD, Pope HG, Jonas JM: Pathological gambling and major affective disorders: preliminary findings. J Clin Psychiatry 1986, 47:201–203.

    PubMed  CAS  Google Scholar 

  16. Specker SM, Carlson GA, Christenson GA, et al.: Impulse control disorders and attention deficit disorder in pathological gamblers. Ann Clin Psychiatry 1995, 7:175–179.

    PubMed  CAS  Google Scholar 

  17. Carlton PL, Goldstein L: Physiological determinants of pathological gambling. In A Handbook of Pathological Gambling. Edited by Glaski T. Springfield: Charles C. Thomas; 1987:657–663.

    Google Scholar 

  18. Stegman M, Regard M, Landis T, et al.: Pathological gambling: neuropsychological and EEG findings. Presented at the 19th Annual Meeting of the International Neuropsychology Society; San Antonio, TX, February 13–19, 1991.

  19. Roy A, Custer R, Lorenz V, et al.: Depressed pathological gamblers. Acta Psychiatr Scand 1988, 77:163–165.

    PubMed  CAS  Google Scholar 

  20. Roy A, Adinoff B, Roehrich L, et al.: Pathological gambling: a psychobiological study. Arch Gen Psychiatry 1988, 45:369–373.

    PubMed  CAS  Google Scholar 

  21. DeCaria C, Hollander E, Nora R, et al.: Gambling: biological/ genetic, treatment, government, and gambling concerns: neurobiology of pathological gambling. Presented at the American Psychiatric Association Annual Meeting; San Diego, CA, May 20, 1997.

  22. Bergh C, Eklund T, Sodersten P, et al.: Altered dopamine function in pathological gambling. Psychol Med 1997, 27:473–475.

    Article  PubMed  CAS  Google Scholar 

  23. Blum K, Braverman ER, Wu S, et al.: Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Mol Psychiatry 1997, 2:239–246.

    Article  PubMed  CAS  Google Scholar 

  24. Comings DE: The molecular genetics of pathological gambling. CNS Spectrums 1998, 3:20–37.

    Google Scholar 

  25. Perez de Castro I, Ibanez A, Torrez P, et al.: Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 1997, 7:345–348.

    Article  PubMed  CAS  Google Scholar 

  26. Tye NC, Iverson SD, Green AR: The effects of benzodiazepines and serotonin manipulations on punished responding. Neuropharmacology 1979, 18:689–695.

    Article  PubMed  CAS  Google Scholar 

  27. Levitt P, Pintar JE, Braekefield XO: Immunocytochemical demonstration of monamine oxidase B in brain astrocytes and serotonin neurons. Proc Natl Acad Sci U S A 1982, 70:6385–6389.

    Article  Google Scholar 

  28. Perris C, Jacobson L, von Knorring L, et al.: Enzymes related to biogenic amine metabolism and personality characteristics in depressed patients. Acta Psychiatr Scand 1980, 61:477–484.

    PubMed  CAS  Google Scholar 

  29. Schalling D, Asberg M: Biological and psychological correlates of impulsiveness and monotony avoidance. In The Biological Foundations of Personality and Behavior. Edited by Strelau J, Farley FH, Gale A. New York: Hemisphere Press; 1985:181–194.

    Google Scholar 

  30. Murphy KL, Belmaker R, Buchsbaum MS: Biogenic amine related enzymes and personality variations in normals. Psychol Med 1977, 7:149–157.

    Article  PubMed  CAS  Google Scholar 

  31. von Knorring L, Oreland L, Winblad B: Personality traits related to monoamine oxidase activity in platelets. Psychiatry Res 1984, 12:11–26.

    Article  Google Scholar 

  32. Ward PB, Catts SV, Norman TR, et al.: Low platelet monoamine oxidase and sensation seeking in males: an established relationship? Acta Psychiatr Scand 1987, 75:86–90.

    PubMed  CAS  Google Scholar 

  33. Buchsbaum MS, Haier RJ, Murphy DL: Suicide attempts, platelet monoamine oxidase, and the average evoked response. Acta Psychiatr Scand 1977, 56:69–79.

    PubMed  CAS  Google Scholar 

  34. Gottfries CG, von Knorring L, Oreland L: Platelet monoamine oxidase activity in mental disorder. II: affective psychoses and suicidal behavior. Prog Neuro Psychopharmacol 1980, 4:185–192.

    Article  CAS  Google Scholar 

  35. Blanco C, Orensanz-Munoz L, Blanco-Jerez C, et al.: Pathological gambling and platelet MAO activity: a psychobiological study. Am J Psychiatry 1996, 153:119–121.

    PubMed  CAS  Google Scholar 

  36. Carrasco J, Saiz-Ruiz J, Moreno I, et al.: Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatr Scand 1994, 90:427–431.

    PubMed  CAS  Google Scholar 

  37. Virkkunen M, Nuutila A, Goodwin F, et al.: Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch Gen Psychiatry 1987, 44:241–247.

    PubMed  CAS  Google Scholar 

  38. Moreno I, Saiz-Ruiz J, Lopez-Ibor JJ: Serotonin and gambling dependence. Human Psychopharmacol 1991, 6(suppl):S9-S12.

    Article  CAS  Google Scholar 

  39. DeCaria CM, Hollander E, Grossman R, et al.: Diagnosis, neurobiology and treatment of pathological gambling. J Clin Psychiatry 1996, 57:80–84.

    PubMed  Google Scholar 

  40. Decaria CM, Begaz T, Hollander E: Serotonergic and noradrenergic function in pathological gambling. CNS Spectrums 1998, 3:38–47.

    Google Scholar 

  41. Rasmussen SA: Obsessive compulsive spectrum disorders. J Clin Psychiatry 1994, 55:89–91.

    PubMed  CAS  Google Scholar 

  42. Perse TL, Greist JH, Jefferson JW, et al.: Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1988, 144:1543–1548.

    Google Scholar 

  43. Goodman WK, Price LH, Rasmussen SA, et al.: The efficacy of fluvoxamine in obsessive compulsive disorder: a doubleblind comparison with placebo. Arch Gen Psychiatry 1989, 46:36–44.

    PubMed  CAS  Google Scholar 

  44. Koran LM, McElroy SL, Davidson JR, et al.: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a doubleblind comparison. J Clin Psychopharmacol 1996, 16:121–129.

    Article  PubMed  CAS  Google Scholar 

  45. Mundo E, Maina G, Uslenghi C: Multicenter, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2000, 15:69–76.

    PubMed  CAS  Google Scholar 

  46. Phillips KA, Dwight MM, McElroy SL: Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998, 59:165–71.

    PubMed  CAS  Google Scholar 

  47. Hollander E, Cohen LJ, Simeon D, et al.: Fluvoxamine treatment of body dysmorphic disorder. J Clin Psychopharmacol 1994, 14:75–77.

    PubMed  CAS  Google Scholar 

  48. Hollander E, Allen A, Kwon J: Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 1999, 56:1033–1039.

    Article  PubMed  CAS  Google Scholar 

  49. Swedo SE, Leonard HL, Rapoport JL, et al.: A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania. N Engl J Med 1989, 321:497–501.

    Article  PubMed  CAS  Google Scholar 

  50. Casals-Ariet C, Cullen K: Exhibitionism treated with clomipramine. Am J Psychiatry 1993, 150:1273–1274.

    PubMed  CAS  Google Scholar 

  51. Zohar J, Zeev K, Benjamin J: Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. J Clin Psychiatry 1994, 55:86–88.

    PubMed  CAS  Google Scholar 

  52. Lepkifker E, Dannon PN, Ziv R, et al.: The treatment of kleptomania with serotonin reuptake inhibitors. Clin Neuropharmacol 1999, 22:40–43.

    Article  PubMed  CAS  Google Scholar 

  53. Hollander E: Obsessive-compulsive spectrum disorders: an overview. Psychiatr Ann 1993, 23:355–358.

    Google Scholar 

  54. Hollander E, Kwon JH, Stein DJ, et al.: Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 1996, 57(suppl 8):3–6.

    PubMed  Google Scholar 

  55. Hollander E: Treatment of obsessive-compulsive spectrum disorders with SSRIs. Brit J Psychiatry 1998, 173(suppl 35):7–12.

    Google Scholar 

  56. Hollander E, Frenkel M, DeCaria C, et al.: Treatment of pathological gambling with clomipramine. Am J Psychiatry 1992, 149:710–711.

    PubMed  CAS  Google Scholar 

  57. Hollander E, DeCaria CM, Mari E, et al.: Short-term singleblind fluvoxamine treatment of pathological gambling. Am J Psychiatry 1998, 155:1781–1783. This paper was the first to examine the short-term efficacy of fluvoxamine on gambling urge and gambling behavior in 10 PG patients. The promising results of this pilot study led researchers to perform double blind studies of SRIs in PG.

    PubMed  CAS  Google Scholar 

  58. Hollander E, DeCaria CM, Finkell JN, et al.: A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000, 47:813–817. This paper examines the short-term efficacy and tolerability of fluvoxamine in the treatment of PG. This was the first randomized, double blind study of fluvoxamine in PG.

    Article  PubMed  CAS  Google Scholar 

  59. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J: A pilot placebocontrolled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002, 14:9–15.

    Article  PubMed  Google Scholar 

  60. Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996, 169:468–474.

    PubMed  CAS  Google Scholar 

  61. Kim SW, Grant JE, Adson DE, et al.: A double-blind placebocontrolled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002, 63:501–507. Kim et al. evaluate the efficacy of paroxetine in the treament of PG. Forty-five PG patients completed a 1-week placebo lead-in followed by an 8-week, double blind, placebo-controlled trial. This is the first paper to examine the efficacy of paroxetine in reducing gambling behaviors and urges.

    PubMed  CAS  Google Scholar 

  62. Montgomery SA, Kasper S, Stein DJ, et al.: Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001, 16:75–86.

    Article  PubMed  CAS  Google Scholar 

  63. Perna G, Bertani A, Caldirola D, et al.: A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001, 34:85–90.

    Article  PubMed  CAS  Google Scholar 

  64. Simon NM, Sharma SG, Worthington JJ, et al.: Citalopram for social phobia: a clinical case series. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:1469–74.

    Article  PubMed  CAS  Google Scholar 

  65. Zimmerman M, Breen RB, Posternak MA: An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002, 63:44–48.

    PubMed  CAS  Google Scholar 

  66. Coleman E, Gratzer T, Nesvacil L, Raymond NC: Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. J Clin Psychiatry 2000, 61:282–284.

    PubMed  CAS  Google Scholar 

  67. Pallanti S, Baldini-Rossi N, Sood E, Hollander E: Nefazadone treatment of pathological gambling: a prospective open label controlled trial. J Clin Psychiatry 2003, In press. This paper examines the efficacy of nefazodone in the treatment of PG. Twelve patients with PG were treated open label with nefazadone for 8 weeks. This is the first paper examining the effectiveness of nefazadone in PG patients.

  68. Herridge P, Gold MS: Pharmacological adjuncts in the treatment of opioid and cocaine addicts. J Psychoactive Drugs 1988, 20:233–242.

    PubMed  CAS  Google Scholar 

  69. Keuler DJ, Altemus M, Michelson D, et al.: Behavioral effects of naloxone infusion in obsessive compulsive disorder. Biol Psychiatry 1996, 40:154–156.

    Article  PubMed  CAS  Google Scholar 

  70. Marrazzi MA, Bacon JP, Kinzie J, Luby ED: Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int Clin Psychopharmacol 1995, 10:163–172.

    PubMed  CAS  Google Scholar 

  71. Roth AS, Ostroff RB, Haffman RE: Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial. J Clin Psychiatry 1996, 57:233–237.

    PubMed  CAS  Google Scholar 

  72. Crockford DN, El-Guebaly N: Naltrexone in the treatment of pathological gambling and alcohol dependence. Can J Psychiatry 1998, 43:86.

    PubMed  CAS  Google Scholar 

  73. Kim SW, Grant JE: An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 2001, 16:285–289.

    Article  PubMed  CAS  Google Scholar 

  74. Kim SW, Grant JE, Adson DE, Shin YC: Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001, 49:914–921. Kim et al. evaluated the short-term efficacy of naltrexone in 45 PG subjects through an 11-week, double blind, placebo-controlled trial.

    Article  PubMed  CAS  Google Scholar 

  75. Howland RH: Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996, 16:425–427.

    Article  PubMed  CAS  Google Scholar 

  76. Go FS, Malley EE, Birmaher B, et al.: Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 1998, 8:73–80.

    Article  PubMed  CAS  Google Scholar 

  77. Diler RS, Avci A: SSRI-induced mania in obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1999, 38:6–7.

    Article  PubMed  CAS  Google Scholar 

  78. Heimann SW, March JS: SSRI-induced mania. J Am Acad Child Adolesc Psychiatry 1996, 35:4.

    Article  PubMed  CAS  Google Scholar 

  79. Hollander E, Allen A, Prieto Lopez R, et al.: A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001, 62:199–203.

    Article  PubMed  CAS  Google Scholar 

  80. Stein DJ, Simeon D, Frenkel M, et al.: An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995, 56:506–510.

    PubMed  CAS  Google Scholar 

  81. Christenson GA, Popkin MK, Mackenzie TB, Realmuto GM: Lithium treatment of chronic hair pulling. J Clin Psychiatry 1991, 52:116–120.

    PubMed  CAS  Google Scholar 

  82. Haller R, Hinterhuber H: Treatment of pathological gambling with carbamazepine. Pharmacopsychiatry 1994, 27:129.

    PubMed  CAS  Google Scholar 

  83. Moskowitz JA: Lithium and lady luck: use of lithium carbonate in compulsive gambling. NY State J Medicine 1980, 80:785–788.

    CAS  Google Scholar 

  84. Pallanti S, Quercioli L, Sood E, Hollander E: Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002, 63:559–564. This paper discusses the efficacy of lithium and valproate in the treatment of PG. Forty-two PG subjects without comorbid bipolar disorder were randomized to lithium or valproate for the 14-week trial. This is the first paper to compare the efficacy of two mood stabilizers in the treatment of PG.

    PubMed  CAS  Google Scholar 

  85. Hollander E, Pallanti S, Baldini-Rossi N, Sood E: Sustained release lithium/placebo treatment response in bipolar spectrum pathological gamblers. Poster presented at the 42nd Annual New Clinical Drug Evaluation Unit Meeting; Boca Raton, FL., June 11, 2002. The authors present data from a 10-week, double blind, placebocontrolled study of sustained-release lithium carbonate versus placebo in 29 bipolar spectrum pathologic gamblers. This is the first double blind, placebo-controlled study of sustained-release lithium carbonate in the treatment of PG.

  86. Hollander E, Begaz T, DeCaria, CM: Pharmacological approaches in the treatment of pathological gambling. CNS Spectrums 1998, 3:72–80.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, The Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230, 10029, New York, NY, USA

    Eric Hollander MD

Authors
  1. Erica D. Sood BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Pallanti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Hollander MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sood, E.D., Pallanti, S. & Hollander, E. Diagnosis and treatment of pathologic gambling. Curr Psychiatry Rep 5, 9–15 (2003). https://doi.org/10.1007/s11920-003-0003-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-003-0003-7

Keywords

Search

Navigation